BPC-157 vs Ipamorelin
Body Protection Compound · GH Secretagogue
Here is how these two compounds compare, based on published research, not marketing claims.
BPC-157
A tissue repair peptide that promotes blood vessel formation and growth factor signaling directly at injury sites; over 200 published studies.
Ipamorelin
The most selective growth hormone secretagogue documented; triggers GH release without raising cortisol, prolactin, or ACTH.
BPC-157
212 studies
4 human trials
Not FDA-Approved
Ipamorelin
48 studies
3 human trials
Not FDA-Approved
What it does
BPC-157
In animal studies, drives new blood vessel formation at injury sites, one of the body's main repair signals in damaged tissue. A short peptide fragment originally isolated from human stomach juice that, in rodent models, ramps up production of growth factors involved in healing (VEGF, EGF, FGF). The angiogenic effect documented in those animal studies is what underlies the recovery claims that made BPC-157 prominent in athletic and post-surgical contexts. Published human evidence remains essentially absent.
Ipamorelin
Releases growth hormone without the cortisol or prolactin spike that older ghrelin agonists produced. The most receptor-selective compound in the GH secretagogue class for GHS-R1a, the ghrelin receptor itself. Comparable growth hormone elevation to GHRP-2 or GHRP-6 in head-to-head studies, without the hormonal collateral that made those compounds harder to study.
How it works
BPC-157
A copy of a small protein the body naturally makes in the stomach. It works by turning up three repair signals (VEGF, EGF, FGF) that tell the body to build new blood vessels. It also nudges the nitric oxide system, which controls blood flow and inflammation. In animal research, the result is the body's own repair process running faster.
Ipamorelin
Ipamorelin acts on a single receptor on the pituitary gland (the ghrelin receptor, GHS-R1a) and triggers growth hormone release without touching the cortisol axis, the prolactin axis, or the appetite signal that older compounds in this class also activated. Other GH secretagogues like GHRP-6 and hexarelin raise cortisol alongside GH, raise prolactin, and sharpen hunger. Ipamorelin does not.
How often
BPC-157
In studies, given as a daily shot under the skin, usually for several weeks at a time. Some studies have looked at oral forms specifically for gut work.
Ipamorelin
In published human pharmacokinetic studies (Johansen 1999), ipamorelin was given as a subcutaneous injection with dose-dependent GH response measured over hours. The Beck 2014 Phase II post-surgical trial used repeated dosing over days. Clinical protocols typically use daily subcutaneous injection, though this frequency derives from clinical practice rather than from controlled dose-optimization trials.
How strong
BPC-157
Local. The action concentrates at the injury rather than spreading body-wide.
Ipamorelin
Moderate GH elevation with the cleanest hormonal profile in the secretagogue class. The GH pulse follows the body's natural pulsatile pattern rather than producing sustained elevation. The selectivity advantage is the pharmacological identity of the molecule.
Main tradeoff
BPC-157
Strong animal data on tendons and gut healing. Human studies are thin. And one quirk: most of the published research traces back to a single research group, which limits how independent the findings are.
Ipamorelin
The selectivity that makes ipamorelin distinctive is well documented, but clinical outcome data beyond the single Phase II post-surgical GI trial (Beck 2014) is absent. One of the most widely used peptides in clinical practice has almost no published outcomes data for the endpoints practitioners actually prescribe it for. The CJC-1295 plus ipamorelin combination has never been tested in a controlled comparison study despite being the most common clinical protocol.
Best for
BPC-157
- Research on a specific local injury: tendons, ligaments, or gut lining
- Research targeting one site rather than a body-wide effect
- Research using daily subcutaneous injection
Ipamorelin
- Research interest in selective GH secretagogues with minimal off-target hormonal effects
- Research comparing GH secretagogue selectivity profiles across the class
- Research contexts where the CJC-1295 plus ipamorelin pairing is the protocol under study
How to choose
A good fit for BPC-157
- Research on a specific local tissue injury: tendons, ligaments, gut lining, or wound healing
- Research targeting repair mechanisms at the injury site rather than systemic hormone elevation
- Research contexts where growth hormone modulation is not the goal
A good fit for Ipamorelin
- Research on growth hormone optimization with minimal off-target hormonal effects
- Research comparing GH secretagogue selectivity profiles across the class
- Research contexts where the CJC-1295 plus ipamorelin pairing is the protocol under study
Consider both across time
BPC-157 and ipamorelin target entirely different biological systems. BPC-157 sends repair signals to damaged tissue locally. Ipamorelin tells the pituitary to release growth hormone systemically. They are not interchangeable for the same research goal; the comparison exists because both appear in peptide research protocols, not because they serve the same biological purpose. Some research protocols combine them to target tissue repair and systemic GH support simultaneously, but no controlled study of the combination has been published.
Dosing should be determined by a qualified physician who can evaluate individual circumstances. PSI does not provide personalized dosing guidance.
Official dosing references
- DailyMed(NIH drug labels)
- ClinicalTrials.gov
- PubMed
For readers who want the biology: here is the pathway each compound uses to signal the body. This section is optional. The comparison above covers the practical differences.
▶See the biology
- Tissue Repair
- Tissue Repair connects to NO System Modulation
- NO System Modulation upregulates VEGF / EGF / FGF
- VEGF / EGF / FGF connects to Blood Vessel Formation
- Blood Vessel Formation connects to Nutrient Delivery
- GHS-R1a Receptor
- GHS-R1a Receptor activates Ghrelin Mimicry
- Ghrelin Mimicry connects to Anterior Pituitary
- Anterior Pituitary connects to Growth Hormone Release
- Growth Hormone Release connects to IGF-1 Elevation
BPC-157 increases growth factors (VEGF, EGF, FGF) that signal the body to build new blood vessels at the injury site.
Ipamorelin selectively binds the ghrelin receptor on pituitary somatotrophs to trigger growth hormone release without raising cortisol or prolactin.
Research Evidence
BPC-157 has a larger total evidence base with over 200 published studies, predominantly animal models covering tendon repair, gut protection, and wound healing. Two human pilot trials from 2024 to 2025 represent the earliest direct human data. Ipamorelin has 48 published studies, including multiple human pharmacodynamic studies confirming the selectivity profile (Raun 1998, Johansen 1999) and a Phase II post-surgical GI recovery trial (Beck 2014). For tissue repair research, BPC-157 has more directly relevant data. For GH secretagogue research, ipamorelin has cleaner pharmacological characterization than any compound in its class.
- 1.
For a specific injury, BPC-157 targets the repair process directly.
- 2.
For systemic GH optimization, ipamorelin is the appropriate tool.
- 3.
For recovery protocols, some practitioners use both, targeting different aspects of recovery.
- 4.
Do not use ipamorelin expecting tissue repair, or BPC-157 expecting GH elevation.
Key Limitations
- •No head-to-head comparison.
- •They are not pharmacological alternatives to each other.
- •Combination use is common but unstudied.
- •Both lack Phase III trials.
Community Discussion
PSI monitors discussions across peptide research and biohacking communities. These are reported experiences, not clinical evidence.
BPC-157
"BPC-157 healed my gut issues in two weeks"
Plausible but unproven in humans
"BPC-157 fixed my tendon injury faster than anything"
Plausible but unproven in humans
"BPC-157 is completely safe with no side effects"
Insufficient evidence
Ipamorelin
"Ipamorelin is the cleanest GH secretagogue with the fewest side effects"
Plausible but unproven
"Combined with CJC-1295 it mimics natural GH pulsing"
Plausible but unproven
"It helped with my joint pain and recovery"
Anecdotal only
Safety Comparison
Both compounds have favorable safety profiles within their respective research contexts. Ipamorelin's defining safety advantage is selectivity: it does not raise cortisol, prolactin, or ACTH at GH-stimulating doses, avoiding the off-target effects that older secretagogues like GHRP-6 and hexarelin carry. BPC-157 has more total safety observations across its larger animal study base, with no serious adverse events in the available human pilot data. Neither compound is FDA-approved. Compounded versions sold in research-peptide markets are not FDA-regulated and may carry purity or contamination risks.
BPC-157
Extensive animal safety data. Two human pilot studies. Not FDA-approved.
Ipamorelin
Minimal off-target effects. Does not raise cortisol or prolactin. Generally well-tolerated.
What the Research Suggests
Different tools. Different toolboxes. BPC-157 for tissue repair. Ipamorelin for GH. Comparing them is only useful if you are deciding which system to target.